Institutional Ownership
Neuphoria Therapeutics Inc
CUSIP 64136E102COMNEUPQ1 2026
13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
6
Distinct reporting persons
Largest Stake
37.1%
Max % of class reported
Institutional Holders
19
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
12 filings · latest Feb 6, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 6, 2026 | Baselake Partners, LP | 13G/A | 4.1% | 222.2K | SEC |
| 2 | Dec 29, 2025 | Lynx1 Capital Management LP | 13D/A | 16.3% | — | SEC |
| 3 | Dec 2, 2025 | Lynx1 Capital Management LP | 13D/A | 16.3% | — | SEC |
| 4 | Nov 28, 2025 | Lynx1 Capital Management LP | 13D/A | 16.3% | — | SEC |
| 5 | Nov 18, 2025 | Lynx1 Capital Management LP | 13D/A | 16.3% | — | SEC |
| 6 | Nov 10, 2025 | Lynx1 Capital Management LP | 13D/A | 26.5% | — | SEC |
| 7 | Nov 5, 2025 | Coastlands Capital LP | 13G | 5.1% | — | SEC |
| 8 | Oct 31, 2025 | Baselake Partners, LP | 13G | 9.4% | 222.2K | SEC |
| 9 | Oct 31, 2025 | Shay Capital LLC | 13G | 11.0% | 171.6K | SEC |
| 10 | Oct 23, 2025 | Lynx1 Capital Management LP | 13D | 37.1% | — | SEC |
2 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Neuphoria Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 875.3K | $3.56M |
| 2 | Advisorshares Investments LLC | 155.4K | $632.3K |
| 3 | Shay Capital LLC | 151.0K | $614.6K |
| 4 | Balyasny Asset Management L.P. | 142.2K | $578.7K |
| 5 | Vanguard Capital Management LLC | 98.5K | $401.0K |
| 6 | Squadron Capital Management LLC | 76.7K | $312.3K |
| 7 | Geode Capital Management, LLC | 52.0K | $211.7K |
| 8 | Ikarian Capital, LLC | 47.4K | $193.1K |
| 9 | Vanguard Fiduciary Trust Co | 33.6K | $136.7K |
| 10 | Adar1 Capital Management, LLC | 30.0K | $122.1K |